Pharmacological V1a-RA
V1a receptor antagonists (balovaptan, RG7713)
The Vasopressin receptor antagonist V1a-RA is a key focus in anxiety and stress research.
AVP affects brain regions involved in anxiety, such as the amygdala, and may be linked to anxiety disorders and post-traumatic stress disorder. Clinical studies show decreased AVP levels following anxiolytic treatment. V1a receptors are abundant in areas like the lateral septum and bed nucleus of the stria terminalis, which are involved in fear and anxiety regulation.
Animal studies have shown that V1a receptor antagonists reduce anxious behavior in various tests, suggesting their potential for anxiety treatment. Clinical research also indicates that genetic variations in the V1a receptor can influence amygdaloid activation to emotional stimuli. The V1a receptor antagonist SRX246 is being evaluated for its effects on non-social fear and anxiety in humans. These findings underscore the importance of targeting the V1a receptor in addressing both anxiety and fear, which may require distinct treatment approaches due to their different underlying neural circuits.
Number of meta-analyses
- Preschool (0-5): no meta-analysis
- School-age (6-12): no meta-analysis
- Adolescents (13-17): no meta-analysis
- Adults (18+): 8 meta-analyses
One meta-analysis per outcome and age group, shown in the Intervention explorer.
See its evidenceReferences 2
- Lee RJ, Coccaro EF, Cremers H et al. (2013) A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study. Front Syst Neurosci 7:1-11
- Meyer-Lindenberg A, Kolachana B, Gold B et al. (2009) Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans. Mol Psychiatry 14:968-975